182 related articles for article (PubMed ID: 26954700)
1. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.
Massey AS; Pentlavalli S; Cunningham R; McCrudden CM; McErlean EM; Redpath P; Ali AA; Annett S; McBride JW; McCaffrey J; Robson T; Migaud ME; McCarthy HO
Mol Pharm; 2016 Apr; 13(4):1217-28. PubMed ID: 26954700
[TBL] [Abstract][Full Text] [Related]
2. Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiforme.
Jena LN; Bennie LA; McErlean EM; Pentlavalli S; Glass K; Burrows JF; Kett VL; Buckley NE; Coulter JA; Dunne NJ; McCarthy HO
J Nanobiotechnology; 2021 May; 19(1):127. PubMed ID: 33947409
[TBL] [Abstract][Full Text] [Related]
3. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
4. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Ishtiaq S; Edwards S; Sankaralingam A; Evans BA; Elford C; Frost ML; Fogelman I; Hampson G
Cytokine; 2015 Feb; 71(2):154-60. PubMed ID: 25461393
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
[TBL] [Abstract][Full Text] [Related]
6. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Oizumi T; Funayama H; Yamaguchi K; Yokoyama M; Takahashi H; Yamamoto M; Kuroishi T; Kumamoto H; Sasaki K; Kawamura H; Sugawara S; Endo Y
J Oral Maxillofac Surg; 2010 May; 68(5):1043-54. PubMed ID: 20156665
[TBL] [Abstract][Full Text] [Related]
8. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
Aft R
Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates as anticancer therapy for early breast cancer.
Mahtani R; Jahanzeb M
Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
[TBL] [Abstract][Full Text] [Related]
11. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
[TBL] [Abstract][Full Text] [Related]
12. N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
Schott H; Goltz D; Schott TC; Jauch C; Schwendener RA
Bioorg Med Chem; 2011 Jun; 19(11):3520-6. PubMed ID: 21536448
[TBL] [Abstract][Full Text] [Related]
13. Potential anticancer properties of bisphosphonates.
Neville-Webbe HL; Gnant M; Coleman RE
Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
[TBL] [Abstract][Full Text] [Related]
14. Nitrogen-containing bisphosphonates and cancer immunotherapy.
Clézardin P; Massaia M
Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
[TBL] [Abstract][Full Text] [Related]
15. Effects of bisphosphonates on human esophageal squamous cell carcinoma cell survival.
Minegaki T; Fukushima S; Morioka C; Takanashi H; Uno J; Tsuji S; Yamamoto S; Watanabe A; Tsujimoto M; Nishiguchi K
Dis Esophagus; 2016 Aug; 29(6):656-62. PubMed ID: 25894100
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Feher A; Koivunemi A; Koivunemi M; Fuchs RK; Burr DB; Phipps RJ; Reinwald S; Allen MR
Bone; 2010 Jan; 46(1):203-7. PubMed ID: 19857619
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Ironside MS; Duer MJ; Reid DG; Byard S
Eur J Pharm Biopharm; 2010 Sep; 76(1):120-6. PubMed ID: 20554022
[TBL] [Abstract][Full Text] [Related]
19. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
20. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
